CL
Celon Pharma S.A.
CLN.WA · WSE
21.95 zł +0.69% (+0.15 zł)
1M +7.35%
Market Cap 1.18B zł
P/E Ratio 10.88x
Div. Yield -
ROE 26.07%
Piotroski F-Score Moderate
5/9Valuation
78 /100
Cheap P/S 5.37x
P/B 2.23x
P/E 10.88x
Growth
49 /100
Stable Book val. growth 8.85%
Rev. growth 9.02%
FCF growth N/A
Profitability
30 /100
Weak Net margin 49.41%
Op. margin 11.93%
FCF margin 15.75%
Quality
49 /100
Average ROE 26.07%
ROA 16.19%
Asset turnover 0.33x
Debt
58 /100
Moderate Current ratio 1.20x
Int. coverage -12.99x
Debt/Equity 0.10x
Stability
39 /100
Moderate Rev. volatility 25.64%
EPS volatility 77.25%
Profitable years 0
Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe
Întreabă StockBot despre CLN.WA
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Maciej Wieczorek
Employees
564
Headquarters
Lomianki